Bradley, Par form licensing, distribution agreement for Adoxa antibiotic

By Angela McDaniels

Seattle, Dec. 14 - Bradley Pharmaceuticals Inc. said it has entered into a licensing and distribution agreement with Par Pharmaceuticals Cos. Inc.

Under the agreement, Par will be the exclusive U.S. distributor of Bradley's generic version of the 50mg and 100mg strengths of Adoxa doxycycline monohydrate tablets, an antibiotic therapy primarily used for the adjunctive treatment of severe acne.

Bradley Pharmaceuticals is a pharmaceutical company based in Fairfield, N.J., that markets to niche physician specialties.

Par is based in Spring Valley, N.Y., and develops branded pharmaceutical products for specialty markets and generic pharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.